STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #363 by analyst upside · 2026-06-20
SNSE
Faeth Therapeutics, Inc.
Healthcare · Market Cap $19M · P/E 0x
ANALYST PRICE TARGET
+273.0%
implied upside to consensus target
Current Price $13.85
Consensus Target $51.67
Bull Target $55.0
Bear Target $50.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
2
Sell
0
52-Week Low $6.33
52-Week High $36.76
YTD Return +84.8%
FUNDAMENTALS
Market Cap $19M
P/E Ratio (TTM) N/A
Forward P/E -3.5x
EPS (TTM) $-142.72
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.33
52-Week High $36.76
Current Price $13.85
Bear Target $50.0
Bull Target $55.0
● Now $13.85 ● Target $51.67
TRADING DATA
Avg Volume 52K
YTD Return +84.8%
Analyst Count 3
Consensus Buy
Upside to Target +273.0%
Last Updated 2026-06-20

ANALYST SUMMARY

Faeth Therapeutics, Inc. (SNSE) is currently trading at $13.85 with a Wall Street consensus price target of $51.67, implying potential upside of 273.0% over the next 12 months. 3 analysts currently cover SNSE, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $55.0, while the most cautious has a target of $50.0.

SNSE operates in the Healthcare sector with a market capitalisation of $19M. The stock is up 84.8% year-to-date and is currently trading near the lower end of its 52-week range of $6.33 – $36.76.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SNSE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-06-15 38% win rate (8 calls)
BTIG ● Initiated
Buy 2026-06-11 38% win rate (8 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-05-29 40% win rate (10 calls)
LUCID CAPITAL MARKETS ● Initiated
Buy 2026-05-28 40% win rate (5 calls)
Citigroup ● Initiated
Buy 2026-05-22 Building track record
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2025-10-30 31% win rate (48 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-08-05 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2025-03-28 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
11/30
Consensus clarity
23/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →